V
25.65
-0.48 (-1.84%)
| Penutupan Terdahulu | 26.13 |
| Buka | 25.98 |
| Jumlah Dagangan | 1,978,105 |
| Purata Dagangan (3B) | 4,333,658 |
| Modal Pasaran | 2,879,161,088 |
| Harga / Buku (P/B) | 3.94 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 22 Apr 2025 - 28 Apr 2025 |
| EPS Cair (TTM) | -1.01 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.13% |
| Nisbah Semasa (MRQ) | 33.09 |
| Aliran Tunai Operasi (OCF TTM) | -87.79 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -55.58 M |
| Pulangan Atas Aset (ROA TTM) | -14.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -17.90% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Viking Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
2.6
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 4.5 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Purata | 2.63 |
|
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.70% |
| % Dimiliki oleh Institusi | 74.22% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 125.00 (Raymond James, 387.33%) | Beli |
| Median | 96.00 (274.27%) | |
| Rendah | 38.00 (Citigroup, 48.15%) | Pegang |
| Purata | 86.29 (236.41%) | |
| Jumlah | 6 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 30.92 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 26 Mar 2025 | 102.00 (297.66%) | Beli | 26.34 |
| 11 Mar 2025 | 102.00 (297.66%) | Beli | 26.52 | |
| Scotiabank | 13 Feb 2025 | 102.00 (297.66%) | Beli | 29.50 |
| B. Riley Securities | 07 Feb 2025 | 96.00 (274.27%) | Beli | 32.56 |
| Citigroup | 07 Feb 2025 | 38.00 (48.15%) | Pegang | 32.56 |
| Maxim Group | 07 Feb 2025 | 70.00 (172.90%) | Beli | 32.56 |
| Piper Sandler | 06 Feb 2025 | 71.00 (176.80%) | Beli | 31.46 |
| Raymond James | 06 Feb 2025 | 125.00 (387.33%) | Beli | 31.46 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |